# Evidence-based assessment/Generalized anxiety disorder (assessment portfolio)

HGAPS is finding new ways to make psychological science conferences more accessible!
Here are examples from APA 2022 and the JCCAP Future Directions Forum. Coming soon... ABCT! ~ More at HGAPS.org ~
* Medical disclaimer: This page is for educational and informational purposes only and may not be construed as medical advice. The information is not intended to replace medical advice offered by physicians. Please refer to the full text of the Wikiversity medical disclaimer.

## What is a "portfolio"?

* For background information on what assessment portfolios are, click the link in the heading above.
Want even 'more' information about this topic? There's an extended version of this page here.

## Preparation phase
### Diagnostic criteria for generalized anxiety disorder

   ICD-11 Diagnostic Criteria
   * Generalised anxiety disorder is characterized by marked symptoms of anxiety that persist for at least several months, for more days than not, manifested by either general apprehension (i.e. ‘free-floating anxiety’) or excessive worry focused on multiple everyday events, most often concerning family, health, finances, and school or work, together with additional symptoms such as muscular tension or motor restlessness, sympathetic autonomic over-activity, subjective experience of nervousness, difficulty maintaining concentration, irritability, or sleep disturbance. The symptoms result in significant distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. The symptoms are not a manifestation of another health condition and are not due to the effects of a substance or medication on the central nervous system.
   Changes in DSM-5
   * The diagnostic criteria for generalized anxiety disorder changed slightly from DSM-IV-TR to DSM-5. Summaries are available here.

### Base rates of GAD in different clinical settings

This section describes the demographic setting of the population(s) sampled, base rates of diagnosis, country/region sampled and the diagnostic method that was used. Using this information, clinicians will be able to anchor the rate of GAD that they are likely to see in their clinical practice.
* To see prevalence rates across multiple disorders, click here.
| Demography | Setting | Base Rate | Diagnostic Method |
| Adults and adolescences in all of U.S.A. | US National Comorbidity Survey Replication (NCS-R; age > = 13) | 0.9% (age 13-17) 2.9% (age 18-64) 1.2% (age >= 65) 2.0% (age >=13) | Fully-structured Composite International Diagnostic Interview (CIDI Version 3.0) |
| Psychiatric outpatients | Individuals seeking treatment in a Psychiatric Outpatient Clinic (age range not reported) | 21% | Structured Clinical Interview for DSM-IV (SCID) |
| Caucasian youth | Children seeking treatment in a Child & Adolescent Anxiety Diagnostic Clinic (age 7 – 18 years old) | 0.39% (parent report) 0.38% (child report) | Anxiety Disorders Interview Schedule for Children for DSM-IV Spence Children's Anxiety Scale (SCAS) |
| Caucasian, African American, Asian American, and Hispanic population | Collaborative Psychiatric Epidemiology Studies (CPES; age >= 18, data merged from three representative national database) | 4.1% (female) 2.1% (male) | World Mental Health Survey Initiative Version of the World Health Organization Composite International Interview (WMH-CIDI) |
| Pennsylvania | Metropolitan Community Sample, all individuals with eating disorders (ages 13 – 65) | 10% | Structured Clinical Interview for DSM-IV (SCID) |
| Adolescents in all of U.S.A. | National Comorbidity Survey Replication Adolescent Supplement (NCS-A; ages 3–18 in the continental U.S) | 2.2% | World Health Organization Composite International Diagnostic Interview (WHO-CIDI) |
| Adolescents in all of U.S.A | National Comorbidity Survey Replication Adolescent Supplement (NCS-A; ages 3–18 in the continental U.S) | 5.4% | Composite International Diagnostic Interview (CIDI) |
| North Carolina | Rural community sample African American and White youth (ages 13-16) | 1.4% | The Child and Adolescent Psychiatric Assessment (CAPA) |
| Texas | Metropolitan Community Sample (ages 11-17) | 0.4% | Diagnostic Interview Schedule for Children, Version IV (DISC-IV) |
| Midwestern Urban | Incarcerated adolescents (ages 10-18) | 1% | Diagnostic Interview Schedule for Children, Version IV (DISC-IV) |
| Non-institutionalized general US population | LGBTQ sample (ages 20-65) | Women: 14.8% same-sex 22.5% bisexual Men: 16.9% same-sex 11.5% bisexual | The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV) |
| Non-institutionalized general US population | Cross-ethnic American population (ages 18+) | White 8.6% African Americans 4.9% Hispanic Americans 5.8% Asian Americans 2.4% | World Mental Health Survey Initiative Version of the World Health Organization Composite International Interview (WMH-CIDI) |
| Outpatient clinics worldwide | Samples across multiple studies worldwide (all ages) | 5% | Clinical evaluations |
| Outpatient clinic worldwide | Samples across multiple studies worldwide (all ages) | 10% | Standardized Diagnostic Interviews (SDIs) |
| People during pregnancy and postpartum | Samples across multiple studies worldwide | 2.4% | Standardized Diagnostic Interviews (SDIs) |
| Older adults | Samples across in Switzerland, German, Italy, England, Spain, and Israel | 3.7% (age 65-69) 3.7% (age 70-74) 2.6% (age 75-79) 2.0% (age >80) | Clinical evaluations |
Search terms: [General Anxiety Disorder] AND [prevalence OR incidence] in GoogleScholar and PsycINFO

## Prediction phase
### Psychometric properties of screening instruments for GAD

The following section contains a list of screening and diagnostic instruments for generalized anxiety disorder. The section includes administration information, psychometric data, and PDFs or links to the screenings.
* Screenings are used as part of the prediction phase of assessment; for more information on interpretation of this data, or how screenings fit in to the assessment process, click here.
* For a list of more broadly reaching screening instruments, click here.
Screening measures for GAD :
| Measure | Format (Reporter) | Age Range | Administration/ Completion Time | Where to Access |
| Penn State Worry Questionnaire (PSWQ) | Questionnaire (Adult Version, Child Version) | 18+ (Adult Version), 6-18 (Child Version) | 4 minutes | PSWQ homepage PSWQ Adult Version PSWQ Child Version PSWC-C Korean PSWQ-C Danish Scoring the PSWQ-C Assessment Center Online Adult Version |
| Screen for Child Anxiety Related Emotional Disorder (SCARED) | Questionnaire (Child, Parent) | 8-19 | 9 or 16 minutes | SCARED homepage SCARED English + Translations & Automatic Scoring Assessment Center Online Youth Version Assessment Center Online Parent Version |
| Child Behavior Checklist (CBCL) | Questionnaire (Parent report) | 6-18 | 10 minutes | ASEBA homepagePurchase |
| Generalized Anxiety Disorder Screener (GAD-7) | Questionnaire (Self-report) | 18+ | 5 minutes | GAD-7 homepage GAD-7 PDF Assessment Center Online Version |
Note: Reliability and validity are included in the extended version. This table includes measures with Good or Excellent ratings.

### Likelihood ratios and AUCs of screening instruments for GAD

* For a list of the likelihood ratios for more broadly reaching screening instruments, click here.
| Screening Measure (Primary Reference) | Area Under Curve (AUC) | LR+ (Score) | LR- (Score) | Clinical Generalizability | Where to Access |
| Penn State Worry Questionnaire (PSWQ) | 0.74 (N=164) | 1.8 (65+) | 0.5 (< 65) | Generalized Anxiety Disorder vs. social anxiety disorder, adults presenting to specialty anxiety clinic | PSWQ Adult Version PSWQ Child Version Assessment Center Online Adult Version |
| Screen for Child Anxiety Related Disorders (SCARED) | .70 (N=243) | 5.0 (+32) | .04 | High: Pure anxiety disorder versus non-anxiety psychiatric disorder, excluding children with disruptive disorder and depression | SCARED English + Translations & Automatic Scoring Assessment Center Online Youth Version Assessment Center Online Parent Version |
| CBCL Anxious/Depressed Scale T-score | .75 (N=1445) | 1.49 (9+) | .67(9-) | Inpatient and outpatient children and adolescents | Purchase |
Note: “LR+” refers to the change in likelihood ratio associated with a positive test score, and “LR-” is the likelihood ratio for a low score. Likelihood ratios of 1 indicate that the test result did not change impressions at all. LRs larger than 10 or smaller than .10 are frequently clinically decisive; 5 or .20 are helpful, and between 2.0 and .5 are small enough that they rarely result in clinically meaningful changes of formulation.
Search terms: [General Anxiety Disorder] AND [children OR adolescents OR pediatric] AND [sensitivity OR specificity] in GoogleScholar and PsycINFO

### Interpreting depression screening measure scores

* For information on interpreting screening measure scores, click here.

## Prescription phase
### Gold standard diagnostic interviews

* For a list of broad reaching diagnostic interviews sortable by disorder with PDFs (if applicable), click here.

### Recommended diagnostic instruments for GAD

Diagnostic instruments for GAD :
| Measure | Format (Reporter) | Age Range | Administration/ Completion Time | Where to Access |
| Anxiety Disorders Interview Schedule for Children/Parent | Structured Interview (Child (ADIS-C), Parent (ADIS-P)) | 6-16 | Varies | Purchase |
| Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5) | Structured Interview (Adult) | 16+ | Varies | Purchase |
| Structured Clinical Interview for DSM-5-Clinician Version (SCID-5-CV) | Structured Interview (Adult ) | 16+ | Varies | Website and purchase |
Note: Reliability and validity are included in the extended version. This table includes measures with Good or Excellent ratings.

## Process phase

The following section contains a list of process and outcome measures for generalized anxiety disorder. The section includes benchmarks based on published norms for several outcome and severity measures, as well as information about commonly used process measures. Process and outcome measures are used as part of the process phase of assessment. For more information of differences between process and outcome measures, see the page on the process phase of assessment.

### Outcome and severity measures

* This table includes clinically significant benchmarks for anxiety specific outcome measures
* Information on how to interpret this table can be found here.
* Additionally, these vignettes might be helpful resources for understanding appropriate adaptation of outcome measures in practice.
* For clinically significant change benchmarks for the CBCL, YSR, and TRF total, externalizing, internalizing, and attention benchmarks, see here.
Clinically significant change benchmarks with common instruments for GAD :
| Measure | Cut-off scores | Cut-off scores | Cut-off scores | Critical Change (unstandardized scores) | Critical Change (unstandardized scores) | Critical Change (unstandardized scores) |
| Benchmarks Based on Published Norms |||||||
| | A | B | C | 95% | 90% | SE$_{difference}$ |
| GAD-7 | -1 | 1.3 | 0.5 | 0.6 | 0.5 | 0.3 |
| PSWQ | 51 | 73 | 59 | 9 | 8 | 4.8 |
| SCARED | 9.9 | 18.1 | 15.3 | 8.9 | 7.5 | 4.5 |
Note: “A” = Away from the clinical range, “B” = Back into the nonclinical range, “C” = Closer to the nonclinical than clinical mean.
Search terms: [General Anxiety Disorder] AND [children OR adolescents OR pediatric] AND [clinical significance OR outcomes] in GoogleScholar and PsycINFO

### Treatment

* Please refer to the page on generalized anxiety disorder for more information on available treatment or go to Effective Child Therapy for a curated resource on effective treatments for GAD.
* For information on conducting Exposure Therapy for anxiety disordered youth, see www.BravePracticeForKids.com

## External Resources

* ICD-10 diagnostic criteria
* Find-a-Therapist
** This is a curated list of find-a-therapist websites where you can find a provider
* NIMH entry about anxiety disorders
* OMIM (Online Mendelian Inheritance in Man)
** 607834
* eMedicine entry about anxiety disorders
* Society of Clinical Child and Adolescent Psychology
* Effective Child Therapy information on Fear, Worry, & Anxiety
** Effective Child Therapy is website sponsored by Division 53 of the American Psychological Association (APA), or The Society of Clinical Child and Adolescent Psychology (SCCAP), in collaboration with the Association for Behavioral and Cognitive Therapies (ABCT). Use for information on symptoms and available treatments.
* Links to SCARED Child, Parent, and Adult + Translations